TROAP

Across TCGA pan-cancer cohorts, TROAP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TROAP data layer compared with 27 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TROAP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TROAP expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.

BRCA, HNSC, and SKCM are the cancer types where TROAP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.416	0.903	<.001	24	view →
HNSC	OS	Median	III,IV	0.187	0.746	.001	20	view →
SKCM	DFS	Median	II,III,IV	0.131	0.712	<.001	6	view →
LIHC	DFS	Median	All	1.000	0.536	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TROAP–BRCA (DFS)

Open the BRCA breakdown →